TPM3 and cancer: The same year pembrolizumab was approved for MSI-high cancers of any type, the first-generation TRK inhibitors larotrectinib and entrectinib were granted breakthrough designation by the US FDA for the treatment of TRK fusion-positive cancers of any histology.